Page last updated: 2024-09-05

lapatinib and ipi-145

lapatinib has been researched along with ipi-145 in 1 studies

Compound Research Comparison

Studies
(lapatinib)
Trials
(lapatinib)
Recent Studies (post-2010)
(lapatinib)
Studies
(ipi-145)
Trials
(ipi-145)
Recent Studies (post-2010) (ipi-145)
1,9193051,442781477

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)ipi-145 (IC50)
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformHomo sapiens (human)0.0147
Phosphatidylinositol 3-kinase regulatory subunit alphaHomo sapiens (human)1.445
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoformHomo sapiens (human)4.0007
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoformHomo sapiens (human)0.2855
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform Homo sapiens (human)0.0232

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chen, XB; Wang, S; Wang, SQ; Yu, B; Yuan, XH; Zhao, W1

Reviews

1 review(s) available for lapatinib and ipi-145

ArticleYear
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
    European journal of medicinal chemistry, 2021, Mar-15, Volume: 214

    Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Humans; Molecular Structure; Neoplasms; Pyrimidines; United States; United States Food and Drug Administration

2021